Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth

Journal of Bone and Mineral Research

Volumn 27, Issue 8, 2012, Pages 1635-1648

  Li, Xin ^a   Ling, Wen ^a   Khan, Sharmin ^a   Yaccoby, Shmuel ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

BONE DISEASE; HOMING; LYMPH NODES; MESENCHYMAL STEM CELLS; MYELOMA; OSTEOBLASTS

Indexed keywords

CYSTEINE RICH PROTEIN 61; DECORIN; GREEN FLUORESCENT PROTEIN; HEME OXYGENASE 1; LUMICAN; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE DISEASE; BONE REMODELING; CELL ACTIVATION; CELL MATURATION; CELL MIGRATION; CELLULAR DISTRIBUTION; CLINICAL EVALUATION; CONTROLLED STUDY; FETUS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENTERY LYMPH NODE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; SCID MOUSE; THERAPY EFFECT; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BONE AND BONES; BONE DISEASES; BONE REMODELING; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DECORIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INJECTIONS, INTRAVENOUS; LYMPH NODES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; MYOCARDIUM; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; RECURRENCE; REMISSION INDUCTION;

EID: 84864148828     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1620     Document Type: Article

References (65)

1. Yaccoby S., Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol. 2010; 149: 311-21.
2. Roodman GD., Skeletal imaging and management of bone disease. Hematology Am Soc Hematol Educ Program. 2008; 313-9.
3. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, Epstein J, van HR, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ., Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007; 25: 1121-8.
4. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B., F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009; 114: 2068-76.
5. Epstein J, Yaccoby S., Consequences of interactions between the bone marrow stroma and myeloma. Hematol J. 2003; 4: 310-4.
6. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J., Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004; 64: 2016-23.
7. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J., Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006; 91: 192-9.
8. Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD Jr, Barlogie B, Yaccoby S., The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood. 2009; 114: 1803-12.
9. Barille S, Collette M, Bataille R, Amiot M., Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood. 1995; 86: 3151-9.
10. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V., Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005; 106: 2472-83.
11. Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, Rizzoli V, Roodman GD, Giuliani N., IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005; 106: 1407-14.
12. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr., The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349: 2483-94.
13. Vallet S, Pozzi S, Patel K, Vaghela N, Fulciniti MT, Veiby P, Hideshima T, Santo L, Cirstea D, Scadden DT, Anderson KC, Raje N., A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia. 2011; 25: 1174-81.
14. Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A., HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood. 2007; 109: 3024-30.
15. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Reme T, Bourin P., Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007; 21: 1079-88.
16. Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, Pandiella A, Hernandez JM, Sanchez-Guijo FM, Del Canizo MC, Gutierrez NC, San Miguel JF., Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia. 2009; 23: 1515-27.
17. Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, Esseltine D, Tricot G., A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica. 2011; 96: 333-6.
18. Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S., The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol. 2009; 84: 6-14.
19. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr., Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007; 109: 2106-11.
20. Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K, Sohani AR, Guimaraes A, Xie W, Chauhan D, Schoonmaker JA, Attar E, Churchill M, Weller E, Munshi N, Seehra JS, Weissleder R, Anderson KC, Scadden DT, Raje N., Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA. 2010; 107: 5124-9.
21. Prockop DJ., Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther. 2009; 17: 939-46.
22. Prockop DJ, Olson SD., Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood. 2007; 109: 3147-51.
23. Uccelli A, Moretta L, Pistoia V., Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008; 8: 726-36.
24. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR., Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284: 143-7.
25. Prockop DJ., " Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin Pharmacol Ther. 2007; 82: 241-3.
26. Karp JM, Leng Teo GS., Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009; 4: 206-16.
27. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK., Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999; 5: 309-13.
28. Parekkadan B, Milwid JM., Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 2010; 12: 87-117.
29. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ., Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009; 5: 54-63.
30. Togel F, Cohen A, Zhang P, Yang Y, Hu Z, Westenfelder C., Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev. 2009; 18: 475-85.
31. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ., Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA. 2006; 103: 17438-43.
32. Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y, Chen C, Chen W, Wang S, Le AD, Shi S., Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res. 2010; 25: 1668-79.
33. Jones BJ, McTaggart SJ., Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol. 2008; 36: 733-41.
34. Ohtaki H, Ylostalo JH, Foraker JE, Robinson AP, Reger RL, Shioda S, Prockop DJ., Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci USA. 2008; 105: 14638-43.
35. Pittenger M., Sleuthing the source of regeneration by MSCs. Cell Stem Cell. 2009; 5: 8-10.
36. Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S., Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol. 2007; 138: 802-11.
37. Pennisi A, Ling W, Li X, Khan S, Wang Y, Barlogie B, Shaughnessy JD Jr, Yaccoby S., Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS ONE. 2010; 5: e15233.
38. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van RF, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr., The molecular classification of multiple myeloma. Blood. 2006; 108: 2020-8.
39. Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J, Yaccoby Y., Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol. 2006; 133: 83-92.
40. Li X, Ling W, Pennisi A, Wang Y, Khan S, Heidaran M, Pal A, Zhang X, He S, Zeitlin A, Abbot S, Faleck H, Hariri R, Shaughnessy JD Jr, van Rhee F, Nair B, Barlogie B, Epstein J, Yaccoby S., Human placenta-derived adherent Cells Prevent Bone loss, Stimulate Bone formation, and suppress growth of multiple myeloma in bone. Stem Cells. 2011; 29: 263-73.
41. Yata K, Yaccoby S., The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia. 2004; 18: 1891-7.
42. Yaccoby S, Barlogie B, Epstein J., Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998; 92: 2908-13.
43. Harrell MI, Iritani BM, Ruddell A., Lymph node mapping in the mouse. J Immunol Methods. 2008; 332: 170-4.
44. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J., Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002; 116: 278-90.
45. Yaccoby S, Epstein J., The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood. 1999; 94: 3576-82.
46. Li X, Pennisi A, Yaccoby S., Role of decorin in the antimyeloma effects of osteoblasts. Blood. 2008; 112: 159-68.
47. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A., Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005; 106: 1755-61.
48. Parekkadan B, Tilles AW, Yarmush ML., Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells. 2008; 26: 1913-9.
49. Barbagallo I, Vanella A, Peterson SJ, Kim DH, Tibullo D, Giallongo C, Vanella L, Parrinello N, Palumbo GA, Di RF, Abraham NG, Asprinio D., Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. J Bone Miner Metab. 2010; 28: 276-88.
50. Sakai E, Shimada-Sugawara M, Nishishita K, Fukuma Y, Naito M, Okamoto K, Nakayama K, Tsukuba T., Suppression of RANKL-dependent heme oxygenase-1 is required for high mobility group box 1 release and osteoclastogenesis. J Cell Biochem. 2012; 113: 486-98.
51. Akiyama T, Dass CR, Shinoda Y, Kawano H, Tanaka S, Choong PF., PEDF regulates osteoclasts via osteoprotegerin and RANKL. Biochem Biophys Res Commun. 2010; 391: 789-94.
52. Broadhead ML, Akiyama T, Choong PF, Dass CR., The pathophysiological role of PEDF in bone diseases. Curr Mol Med. 2010; 10: 296-301.
53. Crockett JC, Schutze N, Tosh D, Jatzke S, Duthie A, Jakob F, Rogers MJ., The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5. Endocrinology. 2007; 148: 5761-8.
54. Si W, Kang Q, Luu HH, Park JK, Luo Q, Song WX, Jiang W, Luo X, Li X, Yin H, Montag AG, Haydon RC, He TC., CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol. 2006; 26: 2955-64.
55. Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC, Anderson KC., The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007; 21: 1007-34, vii-viii.
56. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC., Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood. 1991; 77: 2688-93.
57. Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM., Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer. 2001; 91: 1219-30.
58. Wynn RF, Hart CA, Corradi-Perini C, O'Neill L, Evans CA, Wraith JE, Fairbairn LJ, Bellantuono I., A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood. 2004; 104: 2643-5.
59. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, Liu X, Li Y, Ward CA, Melo LG, Kong D., Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther. 2008; 16: 571-9.
60. Lien CY, Chih-Yuan HK, Lee OK, Blunn GW, Su Y., Restoration of bone mass and strength in glucocorticoid-treated mice by systemic transplantation of CXCR4 and cbfa-1 co-expressing mesenchymal stem cells. J Bone Miner Res. 2009; 24: 837-48.
61. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, Wohlgemuth R., Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med. 2008; 14: 181-7.
62. Shi M, Li J, Liao L, Chen B, Li B, Chen L, Jia H, Zhao RC., Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica. 2007; 92: 897-904.
63. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R., Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 2003; 101: 2999-3001.
64. Togel F, Yang Y, Zhang P, Hu Z, Westenfelder C., Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. Am J Physiol Renal Physiol. 2008; 295: F315-21.
65. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, Battula VL, Weil M, Andreeff M, Marini FC., Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009; 27: 2614-23.